Brooks Labs Board Approves Scheme of Arrangement for Demerger
Brooks Laboratories Limited's Board of Directors has approved a Scheme of Arrangement for the demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited. The demerged undertaking, which includes manufacturing operations at the Baddi facility, sales, exports, and contract manufacturing, accounted for approximately 96.66% of the company's total turnover in FY26, with a turnover of Rs. 8,287.26 lakhs. The rationale includes focused management, realignment of management and ownership, and operational clarity. The scheme requires approvals from stock exchanges, SEBI, NCLT, and shareholders. Post-effectiveness, Abridge Speciality will be renamed Brooks Laboratories Limited, and the demerged company will become Xuri Lifesciences Limited.
Key Highlights
- Board approved demerger of manufacturing business into subsidiary Abridge Speciality.
- Demerged business contributed 96.66% of FY26 turnover (₹8,287.26 Lakhs).
- Scheme aims for focused management and operational clarity.
- Requires approvals from regulatory bodies and shareholders.
- Post-demerger, entities will be renamed Brooks Laboratories and Xuri Lifesciences.
Price Impact
More from BROOKS